Bionano Genomics

About Bionano Genomics

Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions. Through its BioDiscovery business...

CLICK TO LEARN MORE

Bionano Genomics (NASDAQ: BNGO) Stock Quote Follow

Last Trade: US$1.12 0.02 1.36
Volume: 89,352
5-Day Change: -1.33%
YTD Change: -23.63%
Market Cap: US$331.070M

Latest News From Bionano Genomics

March 22, 2023
Bionano Genomics Announces First Study Using OGM to Discover Structural Variants with Potential Relevance to Genetic Diagnosis of MRKH Syndrome, a Syndrome Impacting Reproductive System Development...
Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome is among several forms of Müllerian agenesis, a disorder impacting 1 in 4,500 females which is indicated by the absence or underdevelopment of the female reproductive system Researchers in the study hypothesized that a genome-wide structural variant (SV) analysis would result in... Read More
March 15, 2023
Bionano Laboratories Expands its Clinical Testing Menu with Launch of OGM-Based Laboratory Developed Tests (LDTs) for Prenatal and Postnatal Analysis
SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the expansion of its clinical testing menu with the launch of two new laboratory developed tests (LDTs) based on optical genome mapping (OGM), OGM-Dx TM Postnatal Whole Genome SV and OGM-Dx TM Prenatal Whole Genome SV. These LDTs offer a... Read More
March 13, 2023
Bionano Genomics Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Featuring OGM Utility Across a Broad Range of Research Applications
Bionano CEO and president Dr. Erik Holmlin will participate with Dr. Bruce Korf, president of the ACMG Foundation, in the foundation’s educational and clinical laboratory genetics and genomics (LGG) awards ceremony by presenting the fellowship awards sponsored by Bionano A scientific session on innovations in genomics will... Read More
March 9, 2023
Bionano Genomics Reports Fourth Quarter and Full-Year 2022 Results and Provides Revenue Outlook for 2023
Q4 revenue was $8.2 million, which represents a 30% increase over Q4 2021 2022 revenue was $27.8 million, which represents a 55% increase over year end 2021 Reached installed base of 240 Saphyr® systems as of YE 2022, which represents a 46% increase over YE 2021 Conference call today, March 9 th , 2023 at 4:30 PM ET SAN DIEGO,... Read More
March 2, 2023
Bionano Genomics Announces Two Publications from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing including the First Peer-Reviewed Publication...
Peer-reviewed publication from Iqbal, et al. describes the multi-site evaluation of optical genome mapping (OGM) for postnatal genetic disorders with 404 samples and shows: Concordance of OGM against various standard of care (SOC) methods –99.5% [399 out of 401 samples] First-pass success rate for OGM – 90.2% [369 out of 409... Read More
March 1, 2023
Bionano Genomics to Report Fourth Quarter and Year End 2022 Financial Results and Host a Conference Call and Webcast March 9, 2023
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, March 9 th , 2023 at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2022 and to highlight recent corporate progress.... Read More
February 27, 2023
Bionano Genomics to Present at the 43rd Annual Cowen Healthcare Conference
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that company management will present at the 43rd Annual Cowen Healthcare Conference. Erik Holmlin, Ph.D., Bionano’s president and chief executive officer, is scheduled to present a corporate overview on Monday, March 6th, 2023 at... Read More
February 22, 2023
Bionano Genomics Announces China NMPA Approval for DNA Extraction and Labeling Products for IVD Use in Hematologic Malignancies
Bionano original equipment manufacturing (OEM) partner Beijing Genome Precision Technology (BGPT) obtained reagent class I registration and approval for DNA isolation and labeling kits from China's National Medical Products Administration (NMPA) Reagents can be utilized for in vitro diagnostics use in hematologic malignancies... Read More
HealthStocksHub
February 14, 2023
Bionano Genomics Shares Overview of AGBT Pre-Conference Workshop Program Along with Details of Company’s Innovative Research Grant Opportunity
Bionano leaders presented on the ability of optical genome mapping (OGM) to potentially replace traditional cytogenetic methods for structural variant (SV) detection and shared details of the company’s new product advancements Bionano and NVIDIA previewed their collaborative development, a new compute solution for OGM analysis... Read More
February 9, 2023
Bionano Genomics Strategy Day Highlighted the Company’s Strategic Initiatives and Growth Plans as well as OGM’s Competitive Value for Cell Bioprocessing, and Cancer and Genetic Disease Research
Bionano’s chief executive officer, chief financial officer, chief medical officer, chief operating officer and vice president of clinical and scientific affairs delivered an in-depth review of the company’s strategy, growth drivers, and financial objectives, as well as key initiatives related to clinical trials and new product... Read More
February 2, 2023
Bionano’s Symposium 2023 Featured Record Numbers of Presentations Demonstrating Applications of OGM Across Cell Bioprocessing and Constitutional Genetic Disease and Cancer Research
Over 3,000 registrants with attendees from 114 countries Average daily attendance of 750 in 2023 versus 565 in 2022 31 oral presentations delivered across four consecutive days 69 scientific posters featuring optical genome mapping (OGM) on view in the online exhibit hall On-demand presentations from Symposium available for... Read More
January 24, 2023
Bionano Laboratories Expands its Clinical Testing Menu with Launch of its First OGM-Based Laboratory Developed Test (LDT) for Hematological Malignancies
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the launch of OGM-Dx™ HemeOne™, a laboratory developed test (LDT) based on optical genome mapping (OGM) analysis of blood or bone marrow samples to detect structural variants (SVs) of diagnostic and prognostic utility in individuals with a new or... Read More
January 23, 2023
Bionano Genomics Announces Launch of Next-Generation Versions of its Reagent Kits and Chip Consumable, Along with Updates to its Instrument Control and Bionano Access Software for the Optical Genome...
Bionano Prep SP-G2 (SP-G2) kit offers higher gDNA quality, improved ease-of-use and increased DNA throughput Bionano Prep Direct Label and Stain-G2 (DLS-G2) kit offers increased reagent stability and labeling efficiency resulting in significantly faster sample to results workflow Saphyr Chip® G3.3, instrument control software... Read More
January 20, 2023
Bionano Genomics Announces the Final Speaker Lineup for Symposium 2023 with 30 OGM Presentations and Live Panel Discussions Across a Wide Range of Genetic Disease and Cancer Research Applications
27 different customers representing North America and Europe 30 oral presentations across four consecutive days 34 scientific posters will be featured in a virtual exhibition hall Topics span the application of optical genome mapping (OGM) in genetic disease, cancer research and cell bioprocessing SAN DIEGO, Jan. 20, 2023... Read More
January 18, 2023
Bionano Genomics Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal Testing
IRB-approved, multi-site, ongoing study evaluated 200 samples representing 123 unique prenatal cases across 9 sites for interim measures of key endpoints: Results of OGM analysis were comparable, in a single assay, to the results of two separate standard of care (SOC) tests needed to reach a diagnosis in 56% of cases (69/123)... Read More
January 12, 2023
Bionano Genomics to Accelerate Data Processing Solution for Optical Genome Mapping Workflow with NVIDIA
SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a collaboration with NVIDIA to develop an acceleration platform for use in Bionano’s optical genome mapping (OGM) workflow. This collaboration is expected to significantly improve data processing speed while reducing time and... Read More
January 11, 2023
Bionano Genomics Announces Publication from Institut Curie Showing Utility of OGM for Detection of HRD in Breast Cancer
SAN DIEGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study analyzing optical genome mapping (OGM) as a method to identify homologous recombination deficiency (HRD) in breast cancer samples. The study reported that OGM successfully assessed levels of HRD in all... Read More
January 10, 2023
Bionano Genomics Announces 2023 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Genetic Disease and Cancer Applications
SAN DIEGO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced its 2023 Symposium, which is the quintessential event for the optical genome mapping (OGM) community to present its progress to the world. It will feature four consecutive days of OGM presentations delivered by 25 different customers... Read More
January 6, 2023
Bionano Genomics to Host Strategy Day on February 2, 2023 in New York City
SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host its first-ever Strategy Day on Thursday, February 2nd, 2023, at the Nasdaq MarketSite in New York City, starting at 1:30 PM ET. The event will include presentations from members of the company's leadership team and... Read More
January 5, 2023
Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2022 Results
Preliminary Q4 revenue expected to be between $8.1 and $8.4 million; 29% to 33% increase over Q4 2021 Reached installed base of 240 systems as of YE 2022; 46% increase over YE 2021 Achieved or exceeded all stated goals and milestones for the full year 2022 SAN DIEGO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.... Read More
December 9, 2022
Bionano Genomics: Multi-Center Research Study Illustrates How OGM Can Potentially Result in More Patients Qualifying for Treatments in Leukemia
Researchers from eight research institutes recommend OGM as first-line analysis for AML due to its ability to perform better and cost less than analysis with karyotyping, FISH, and CMA OGM identified pathogenic variants in 12% of cases that altered ELN risk-level or identified eligibility for clinical trials OGM had 100%... Read More
December 8, 2022
Bionano Genomics Announces American Society of Hematology (ASH) Annual Meeting Presentations Featuring OGM Utility Across Blood Cancer Research Applications
A scientific workshop will feature Dr. Rashmi Kanagal-Shamanna from the University of Texas MD Anderson Cancer Center delivering a presentation on the use of emerging technologies for prognostication and research into myeloid neoplasms Four scientific posters featuring results from OGM applications in myeloid cancers, acute... Read More
November 28, 2022
Bionano Genomics to Acquire Purigen Biosystems to Enable Further Simplified and Accelerated DNA Isolation for Optical Genome Mapping (OGM) and Address Difficult Sample Types in New Applications with...
Acquisition adds isotachophoresis (ITP), a proprietary technology licensed exclusively from Stanford University and developed by Purigen Biosystems for isolation and purification of nucleic acids, to the arsenal of tools for potentially simplifying ultra high molecular weight (UHMW) DNA isolation and purification for optical... Read More
November 21, 2022
Bionano Genomics: Publication Shows Utility of OGM in Solid Tumor Research with Study on Detection of Complex Genomic Rearrangements in Prostate Cancer
SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study utilizing optical genome mapping (OGM) to detect structural variants (SVs) and balanced rearrangements relevant to prostate cancer (PCa) pathogenesis. OGM identified SVs in all samples, potentially improving the success rate for finding pathogenic variants and streamlining the detection process. In... Read More
November 10, 2022
Bionano Genomics Appoints Donna Polizio as First Ever Global Head of Market Access
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionano’s focus on advancing the adoption of optical genome mapping (OGM) and working to meet market needs. Ms. Polizio was most recently the vice... Read More
October 28, 2022
Bionano Genomics Announces Extensive Lineup of Content at Association for Molecular Pathology (AMP) Annual Meeting Featuring OGM Utility Across Broad Range of Research Applications
Dr. Alka Chaubey, chief medical officer at Bionano, Dr. Nikhil Sahajpal, Greenwood Genetic Center, Dr. Rashmi Kanagal-Shamanna, MD Anderson Cancer Center, and Dr. Adam Smith, University Health Network will host a sponsored vendor presentation on studies that include multiple types of hematological malignancies, and highlight the benefits of combining optical genome mapping (OGM) with next generation sequencing (NGS) to... Read More
October 27, 2022
Bionano Genomics to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast on November 3, 2022
Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, November 3, 2022 at 4:30 p.m. Eastern Time to report financial results for the third quarter 2022 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Thursday, November 3, 2022 Time: 4:30 p.m. Eastern Time Live Call: Toll Free: 1-877-502-9276 Toll/International: 1-720-543-0302 Live... Read More
October 26, 2022
Hamilton and Bionano Genomics Announce Commercial Availability of World’s First Ultra High Molecular Weight DNA Extraction Automation Solution for OGM
Hamilton and Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that the Long String VANTAGE, a system for automated, high throughput isolation of ultra high molecular weight (UHMW) DNA for use in optical genome mapping (OGM) is commercially available. The Long String VANTAGE is the result of collaborative development from the companies and features new and innovative tools and consumables used for consistent,... Read More
October 24, 2022
Bionano Genomics Announces Global User Event at Bionano Laboratories Before American Society of Human Genetics (ASHG) Annual Meeting
Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the company will host a “Meet the User” event today, October 24, 2022, at its new CLIA-certified Bionano Laboratories facility in advance of the American Society of Human Genetics (ASHG) Annual Meeting 2022. The event is the first scientific user meeting in the company’s history to bring together researchers curious about optical genome mapping (OGM) and experienced users,... Read More
October 20, 2022
Bionano Genomics Announces Presentation of OGM Utility Across Key Applications at American Society of Human Genetics (ASHG) Annual Meeting
Dr. Alka Chaubey, chief medical officer at Bionano, and Dr. Nikhil Sahajpal, fellow at Greenwood Genetic Center, will host a sponsored vendor presentation on a large clinical study utilizing optical genome mapping (OGM) for analysis of postnatal genetic disorders and the complementary use of OGM and next generation sequencing... Read More
October 14, 2022
Bionano Genomics: OGM Evaluated as a Method for Investigating Abnormal NIPT Results due to its Ability to Detect Chromosomal Structural Variations Found in Recurrent Pregnancy Loss
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a peer-reviewed study evaluating optical genome mapping (OGM) as a method for investigating abnormal noninvasive prenatal testing (NIPT) results because of its ability to accurately identify complex structural aberrations relevant to recurrent pregnancy loss and infertility. In a case study from Hangzhou Maternity and Child Care Hospital, researchers... Read More
October 6, 2022
Bionano Genomics Announces Six User Presentations of OGM Results in Cancer Genomics Research at the Spanish Society of Hematology (SEHH) 2022
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation at the Spanish Society of Hematology (SEHH) 2022 Conference, with six scientific presentations from independent researchers covering a wide variety of the cancer genomics landscape, highlighting the application of optical genome mapping (OGM) for hematologic malignancies and cancer research. SEHH 2022 is a three-day conference dedicated to basic,... Read More
October 4, 2022
Bionano Genomics Announces Publication of Study from Sorbonne Université Showing that WGS Identified only 63% of Structural Variations that OGM Detected in Liver Cancer
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study showing the use of optical genome mapping (OGM) to investigate a molecular subgroup of hepatocellular carcinoma (HCC), which is the most common form of liver cancer, in order to explore the complex structural variations (SVs) induced by replication stress. In this study, OGM helped unravel replication stress-induced events, which may cause or... Read More
September 26, 2022
Bionano Genomics to Provide Enhanced Genetic Counseling and Patient Care for Genetic Disorders with OptraHEALTH’s HealthFAX™
Bionano Laboratories and OptraHEALTH today announced their collaboration to utilize HealthFAX’s proprietary AI platform to enhance genetic counseling services and improve care for patients receiving diagnostic services through the Bionano Laboratories. Bionano Laboratories utilizes cutting-edge technologies to provide genetic diagnostics in both clinical and research settings. Bionano Laboratories intends to scale its... Read More
September 23, 2022
Bionano Genomics Announces Launch of CLIA-Certified Bionano Laboratories, and Expands its Clinical Testing Menu with Launch of First OGM-Based LDT for FSHD
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the launch of Bionano Laboratories, a new organization that combines Bionano’s optical genome mapping (OGM) data services with the clinical testing services previously offered by Lineagen, and the launch of Bionano Laboratories’ first OGM-based laboratory developed test (LDT). Bionano Laboratories recently received CLIA-certification for its lab in San Diego. This... Read More
September 21, 2022
Bionano Genomics Announces Publication of Study Using OGM for Detection of Balanced Chromosomal Rearrangements Found in Recurrent Pregnancy Loss
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study utilizing OGM to detect cryptic balanced chromosomal rearrangements (BCRs) found in subjects who experienced recurrent pregnancy loss (RPL). Compared to traditional cytogenetic methods, OGM successfully identified cryptic reciprocal translocation in all samples, improving the success rate for finding pathogenic variants of cryptic BCRs and... Read More
September 14, 2022
Bionano Genomics Announces Publication of Study in MDS and AML Showing Utility for Refined Diagnostics and Prognostic Stratification
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study evaluating the performance of OGM for detection of cytogenetic abnormalities in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) samples. This work is the second independent study, following a recent publication from researchers at MD Anderson Cancer Center, showing that OGM enables better molecular characterization of MDS. This... Read More
September 7, 2022
Bionano Genomics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
Bionano Genomics, Inc. (BNGO) announced today that company management will participate virtually at the H.C. Wainwright 24 th Annual Global Annual Global Investment Conference, taking place September 12-14, 2022. A pre-recorded presentation will be available on the Investor Resources page of the Company's website on Monday, September 12 at 7:00 am ET. About Bionano Genomics Bionano Genomics is a provider of genome analysis... Read More
August 25, 2022
Bionano Genomics Announces the First Publication Using OGM to Analyze Impact of Chromothripsis and TP53 Abnormalities on Chronic Lymphocytic Leukemia (CLL) Patients with High Genomic Complexity
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to use optical genome mapping (OGM) to analyze the impact of chromothripsis (cth) and TP53 abnormalities on chronic lymphocytic leukemia (CLL) patients with high genomic complexity. Researchers aimed to determine whether poor prognostic outcomes observed in cases with cth might be related not only to the chromothriptic event itself but... Read More
August 11, 2022
Bionano Genomics Announces First Publication Using OGM for Detection of Repeat Expansions in CANVAS and Adult-Onset Ataxia
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to evaluate the utility of optical genome mapping (OGM) in the analysis of repeat expansion disorders. Repeat expansion disorders are a class of disorders that impact approximately 1 in 3,000 people and are caused by expansions of short tandem DNA repeats. Researchers in this study describe how OGM can be adopted as an alternative to... Read More
HealthStocksHub
August 4, 2022
Bionano Genomics Reports Second Quarter 2022 Financial Results and Highlights Recent Business Progress
73% year-over-year revenue growth in Q2 2022 Achieved all 1H 2022 ELEVATE! milestones Strong balance sheet with $187.3 million in cash, cash equivalents, and available-for-sale securities at the end of Q2 2022 Conference call today, August 4th, 2022 at 4:30 PM ET Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome... Read More
August 1, 2022
Bionano Genomics Announces Publication of Landmark Research Study in Myelodysplastic Syndrome Showing OGM Data would Result in Revised Prognostic Risk Classification or Additional Actionable Variants in 28% of Study Participants
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to evaluate the utility of optical genome mapping (OGM) for myelodysplastic syndrome (MDS) prognostication. In the peer-reviewed study, published in Leukemia , researchers from The University of Texas MD Anderson Cancer Center reported that when OGM was used instead of karyotyping, 17 to 21% of study subjects had different prognostic... Read More
July 28, 2022
Bionano Genomics to Report Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022
Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, August 4th, 2022 at 4:30 p.m. Eastern Time to report financial results for the second quarter 2022 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Thursday, August 4, 2022 Time: 4:30 p.m. Eastern Time Live Call: Register here for dial-in number and pin Live Webcast:... Read More
July 26, 2022
Bionano Genomics Announces its Participation at the Cancer Genomics Consortium 2022 Annual Meeting with 18 OGM Presentations Covering the Cancer Genomics Landscape
Dr. Alka Chaubey, chief medical officer at Bionano, will host a sponsored vendor panel presentation on the integration of optical genome mapping (OGM) and next generation sequencing (NGS) for clinical research in leukemia and lymphoma Four scientific platform presentations, one each by Dr. Ha Nguyen, MD Anderson Cancer Center, Dr. Adam Smith, University Health Network, Dr. Thuy Phung, University of South Alabama, and Dr.... Read More
July 21, 2022
Bionano Genomics Announces Publication of a New Study Using OGM to Investigate Chromosome Instability during Culture of Induced Pluripotent Stem Cells
Bionano Genomics, Inc. (Nasdaq: BNGO), today announced publication of a study using optical genome mapping (OGM) to investigate numerical and structural changes to two induced pluripotent stem cell (iPSC) lines, WTC-11 and Tuba1-GFP, during long-term culturing. This research provides scientific and practical support for the use of OGM workflows in regenerative medicine due to OGM’s ability to detect hundreds of structural... Read More
June 29, 2022
Bionano Genomics Announces Issuance of a U.S. Patent for Analysis of Small Nucleic Acid Fragments in Nanochannel Arrays
Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that the United States Patent and Trademark Office issued US Patent No.11,359,244 on June 14, 2022. The patent, titled “CHARACTERIZATION OF MOLECULES IN NANOFLUIDICS” claims methods for the analysis of small nucleic acid fragments in nanochannel arrays, which Bionano has traditionally used to analyze ultra-high molecular weight (UHMW) DNA for the identification of... Read More
June 16, 2022
Bionano Genomics Announces Participation at the European Association for Cancer Research (EACR) Congress 2022 Featuring OGM Applications for Cancer Research
Bionano will exhibit its solutions relevant to cancer research: the Saphyr ® system, NxClinical™ software and expert laboratory services A corporate satellite presentation by Alicia Bertolotti, Bionano, Dr. Sylvia Genovese, Bambino Gesù Children’s Hospital, and Dr. Juan Díaz-Martín, Institute of Biomedicine of Sevilla (IBiS), will cover the use of OGM for clinical research applications in solid tumor analysis 3 poster... Read More
June 10, 2022
Bionano Genomics Announces Participation at the European Society of Human Genetics Conference (ESHG) 2022 Featuring OGM Across a Broad Range of Clinical Research Applications and a Collaborative Product Development with Hamilton
The Long String VANTAGE for DNA isolation, a collaborative development between Bionano and Hamilton, and the world’s first automation solution for Ultra High Molecular Weight (UHMW) extraction used in optical genome mapping (OGM), will be on display at the conference A corporate satellite presentation by Dr. Detlef Trost, Laboratoire CERBA, and Dr. Alexander Hoischen, Radboud UMC, will cover the latest research on OGM for... Read More
June 9, 2022
Hamilton and Bionano Genomics Announce World’s First Ultra High Molecular Weight DNA Extraction Automation Solution for OGM
Hamilton and Bionano Genomics, Inc . (Nasdaq: BNGO) today announced the collaborative development of the Long String VANTAGE for the isolation of Ultra High Molecular Weight (UHMW) DNA for use in optical genome mapping (OGM). Extraction of UHMW DNA of high quality and quantity is an important prerequisite and first step in Bionano’s sample preparation workflow. UHMW DNA extraction is generally performed manually by highly... Read More
June 8, 2022
Bionano Genomics Announces Publication of a New Study Using OGM to Investigate Inversions that May Lead to Genetic Disorders
Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the publication of a multi-platform study using OGM in combination with other cytogenetic technologies as a comprehensive strategy to investigate inversions that may lead to... Read More
June 3, 2022
Bionano Genomics Announces Canadian College of Medical Geneticists Presentation Featuring Applications of OGM for Genetic Research
Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced that researchers from University Health Network in Toronto, Columbia University Medical Center, and Children’s Hospital of Eastern Ontario will deliver a two-hour... Read More
June 2, 2022
Bionano Genomics Announces Participation at the Advances in Genome Biology and Technology (AGBT) General Meeting 2022
Dr. Alka Chaubey, chief medical officer of Bionano, will present a spotlight session titled “OGM + NGS for Transforming Genome Biology: The Future is Bright!” Bionano is a Bronze Sponsor at the conference, and will host customers, KOLs and VIPs from the genomics, cytogenetics, and investment communities at an evening reception Conference attendees can experience the Saphyr system and view live demonstrations of Bionano’s... Read More
May 26, 2022
Bionano Genomics Announces Glass Lewis Recommendation and Encourages Stockholders to Cast their Vote Ahead of June 9th Annual Meeting
Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced that Glass Lewis & Co., a leading independent proxy advisory firm, has recommended that Bionano’s stockholders vote in favor of all proposals recommended by Bionano’s Board... Read More
May 26, 2022
Bionano Genomics: First Published Study of OGM in Pediatric AML Shows OGM Identifies MRD Markers and other Novel Variants that Can Impact Case Management
Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the publication of the first peer-reviewed research study using optical genome mapping (OGM) to analyze genetic aberrations found in pediatric patients with acute myeloid... Read More
May 17, 2022
Bionano Genomics to Present at the 2022 H.C. Wainwright Global Investment Conference
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced its virtual participation in the 2022 H.C. Wainwright Global Investment Conference. Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present a company overview... Read More
May 13, 2022
Bionano Genomics Announces Participation at the 2022 American Cytogenomics Conference (ACC) and a User Spotlight Event at Augusta University, a Center of Excellence for OGM
For the first time at this conference, Bionano will exhibit all of its cytogenetic research solutions: OGM solutions, NxClinical software and laboratory services In a dedicated OGM scientific session, six presentations will illustrate the application of Bionano’s OGM in prenatal and postnatal testing, constitutional disease, and cancer Dr. Soheil Shams, chief informatics officer of Bionano, will present a scientific session... Read More
May 12, 2022
Bionano Genomics Announces a Publication From the First Affiliated Hospital of Zhengzhou Highlighting the Utility of OGM
Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the publication of an evaluation of OGM from The First Affiliated Hospital of Zhengzhou, the largest hospital in Central China, highlighting the utility of OGM for structural... Read More
May 5, 2022
Bionano Genomics Reports First Quarter 2022 Financial Results and Highlights Recent Business Progress
80% year-over-year revenue growth in Q1 2022 Achieved all Q1 2022 ELEVATE! milestones Strong balance sheet with $216.5 million in cash, cash equivalents, and available-for-sale securities at the end of Q1 2022 Conference call today, May 5th, 2022 at 4:30 PM ET Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of NxClinical™ software, a leading... Read More
April 29, 2022
Bionano Genomics Announces Peer-Reviewed Publication of NeuroSCORE Model to Predict and Prioritize Human Genes Contributing to Neurodevelopmental Disease
Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced a peer-reviewed publication in Nature detailing the development of NeuroSCORE, a software-based method of analyzing complex genetic conditions that predicts and prioritizes... Read More
April 28, 2022
Bionano Genomics to Report First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 5, 2022
Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, May 5th, 2022 at 4:30 p.m. Eastern Time to report financial results for the first quarter 2022 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Thursday, May 5, 2022 Time: 4:30 p.m. Eastern Time Toll Free: 1-800-239-9838 International: 1-720-543-0214 Conference ID: 2258678... Read More
April 14, 2022
Bionano Genomics Announces Issuance of Two U.S. Patents for Novel Methods that Expand Patent Protection for Uses of Nanochannel Arrays in Genome Analysis
Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced that the United States Patent and Trademark Office issued two new US Patents, No. 11,291,999 and No. 11,292,713 on April 5, 2022. The ‘999 patent, titled “Photocleavage... Read More
April 7, 2022
Bionano Genomics Announces Release of Version 6.2 of its NxClinical Software with Significant New Capabilities for Cancer Research Applications Including HRD Analysis
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the launch of an integrated genomic scar analysis for homologous recombination deficiency (HRD) in the version 6.2 software release of N x Clinical. This feature provides a... Read More
April 6, 2022
Bionano Genomics Announces Publication of a New Study Using OGM Combined with Multiple Analytical Methods Including Single-Cell Analysis as a Comprehensive Molecular Strategy to Characterize the Genomic Variation in B-cell Acute Lymphoblastic...
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the publication of a new study using OGM in combination with multiple other cytogenetic methods and a new single-cell analysis method as a comprehensive molecular strategy to... Read More
April 5, 2022
Bionano Genomics Announces Participation at the American Association for Cancer Research Annual Meeting Spotlighting Optical Genome Mapping Applications and Enhanced NxClinical Capabilities for Cancer Research
Bionano will exhibit all of its solutions relevant to cancer research: OGM systems, NxClinical software and expert laboratory services Exhibitor Theater presentation will share the latest OGM research on comprehensive genomic structural variation and homologous recombination deficiency (HRD) analysis from tumor biopsies Three scientific poster presentations will illustrate the application of Bionano’s OGM in hematological... Read More
March 25, 2022
Bionano Genomics Announces Speaker Lineup for 2022 China Symposium
SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO ), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the final speaker lineup for its 2022 China Symposium. The Symposium will be held March 26, 2022, and features 9 presentations... Read More
March 23, 2022
Bionano Genomics to Present at the 2022 Maxim Virtual Growth Conference
SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, announced today that company management will present at the 2022 Maxim Virtual Growth Conference. Erik Holmlin, PhD, Bionano’s president and chief... Read More
March 23, 2022
Bionano Genomics Announces its Participation at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting with Six Posters and All of its On-Market Solutions on Display
Bionano is back in-person at the ACMG annual meeting – this time as ONE COMPANY with MORE SOLUTIONS For the first time, Bionano will exhibit all of its products and solutions with its combined commercial teams together [in one location] Optical Genome Mapping Solutions, Testing and Laboratory Services, & Software Six scientific posters will illustrate the capabilities and scope of Bionano’s solutions for impacting clinical... Read More
March 18, 2022
Bionano Genomics Announces Publication of Comprehensive Validation of Optical Genome Mapping for Hematologic Neoplasms
Key findings from evaluation of 59 Heme Samples and 10 Controls: OGM detected 162/164 SVs detected by standard cytogenetics methods of karyotyping and FISH OGM detected chromosomal aberrations missed by karyotyping and FISH in 35 cases OGM Sensitivity: 98.7% OGM Specificity: 100% Positive Predictive Value: 100% Negative Predictive Value: 98% OGM Accuracy: 99.2% First-Pass Success Rate: 100% Limit of Detection (LOD) for... Read More
March 8, 2022
Bionano Genomics to Present at the 32nd Annual Oppenheimer Healthcare Conference
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, a leading software solution for visualization, interpretation, and reporting of genomic data, announced today that company management will present virtually at the 32 nd Annual Oppenheimer Healthcare Conference. Erik Holmlin, PhD, Bionano’s president and chief executive officer, is scheduled... Read More
March 7, 2022
Bionano Genomics Appoints Dr. Aleks Rajkovic to its Board of Directors
Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today announced the appointment of Aleks Rajkovic, MD, PhD, to its board of directors. Dr. Rajkovic is currently the Chief Genomics Officer at the University of California, San Francisco... Read More
March 3, 2022
Bionano Genomics to Present at the 42nd Annual Cowen Healthcare Conference
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clincial™, a leading software solution for visualization, interpretation and reporting of genomic data, announced today that company management will present virtually at the 42 nd Annual Cowen Healthcare Conference. Erik Holmlin, Ph.D., Bionano’s chief executive officer, is scheduled to present a... Read More
March 1, 2022
Bionano Genomics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Revenue Outlook for 2022
Full-year 2021 revenue growth of 111% over 2020 Achieved publicly announced anticipated milestones for 2021 Strong balance sheet with $250.6 million in cash, cash equivalents, and available-for-sale securities as of YE 2021 Conference call today, March 1 st , 2022 at 4:30 PM ET Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clincial™, a... Read More
February 22, 2022
Bionano Genomics to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 1st, 2022
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 1 st , 2022 at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2021 and to highlight recent corporate progress. Conference Call & Webcast Details Date: Tuesday, March 1 st , 2022 Time: 4:30 p.m. Eastern Time Toll Free: 1-855-940-5312 Toll/International:... Read More
February 22, 2022
Bionano Genomics Announces Publication of Prospective Study Demonstrating Performance Improvements from OGM in the Analysis of AML and MDS Compared to Traditional Methods
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today announced the publication of a peer-reviewed, prospective study comparing OGM to traditional methods and demonstrating improved sensitivity and lower cost of OGM in the analysis of acute... Read More
February 14, 2022
Bionano Genomics Appoints Helene Klein as its First Ever Chief People Officer
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today announced that it has appointed Helene Klein as its chief people officer, further strengthening its leadership team. As the company expands, culture and employee experience become key success... Read More
February 11, 2022
Bionano Genomics Announces First Publication Demonstrating OGM as an Alternative to Karyotyping for Product of Conception Sample Analysis
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today announced the first publication demonstrating OGM as an alternative to karyotyping (KT) for products of conception (POC) sample analysis. Chromosomal abnormalities are the most common cause of... Read More
February 9, 2022
Bionano Genomics to Present at the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solution for visualization, interpretation and reporting of genomic data, announced today that company management will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Erik Holmlin, PhD, Bionano’s president and chief... Read More
January 26, 2022
Bionano Genomics Announces Publication of the First Study to Combine OGM and NGS to Evaluate Myeloid Cancers
Whole genome analysis by OGM together with analysis using a 523-gene NGS panel can perform better and cost less than analysis with karyotyping, FISH, and a 54-gene NGS panel First study to publish results using N x Clinical software for simultaneous visualization and interpretation of sequence and copy number variants from NGS and OGM data Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on... Read More
January 20, 2022
Bionano Genomics Announces Publication by International COVID-19 Host Genome Structural Variation Consortium Describing How OGM Identified Structural Variations as Predisposing Factors Associated with Severe COVID-19
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, today announced the publication of a study that described the use of OGM to identify rare human genomic structural variants (SVs) as predisposition factors associated with severe COVID-19,... Read More
January 19, 2022
UPDATE -- Bionano Genomics Announces its Support for the ACMG Foundation for Genetic and Genomic Medicine and its Next Generation Fellowship & Residency Training Awards Program
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, today announced that it will financially support the ACMG Foundation for Genetic and Genomic Medicine and its Next Generation Fellowship & Residency Training Awards Program in genetics and... Read More
January 19, 2022
Bionano Genomics Announces its Support for the AGMG Foundation for Genetic and Genomic Medicine and its Next Generation Fellowship & Residency Training Awards Program
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, today announced that it will financially support the ACMG Foundation for Genetic and Genomic Medicine and its Next Generation Fellowship & Residency Training Awards Program in genetics and... Read More
January 19, 2022
Bionano Genomics Announces Record Daily Attendance for 2022 Symposium with 63% Increase Relative to Last Year
Average daily attendance of 565 in 2022 versus 346 in 2021 Over 4,000 registrants with attendees represented from 82 countries 31 oral presentations delivered across four consecutive days 37 scientific posters featuring OGM in the online exhibit hall On-demand presentations from Symposium available for remainder of 2022 Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system... Read More
January 13, 2022
Bionano Genomics Hosts Final Day of 2022 Symposium with Presentations Demonstrating the Combined Detection Power of OGM and NGS
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, capped off the last day of 2022 Symposium, the Company’s premiere event showcasing OGM research applications across key clinical areas of constitutional genetic disease, hematologic malignancies,... Read More
January 12, 2022
Bionano Genomics Hosts Day 3 of 2022 Symposium with New Research Demonstrating Applications of OGM in Solid Tumor Analysis
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, hosted the third day of 2022 Symposium, the Company’s premiere event showcasing OGM research applications across key clinical areas of constitutional genetic disease, hematologic malignancies,... Read More
January 12, 2022
Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2021 Results
Preliminary Q4 revenue expected between $5.8 and $6.2 million; 45%-55% increase over Q4 2020 Reached installed base of 164 systems: 69% increase over YE 2020 Achieved or exceeded all stated goals and milestones for the full year 2021 Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solutions for visualization,... Read More
January 11, 2022
Bionano Genomics Hosts Day 2 of 2022 Symposium with New Research Demonstrating How OGM Detects Known and Novel Variants in Hematologic Malignancies
SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, hosted the second day of 2022 Symposium, the Company’s premiere event showcasing OGM research applications across key clinical areas of constitutional... Read More
January 10, 2022
UPDATE - Bionano Genomics Hosts Day 1 of 2022 Symposium with Six Presentations Highlighting the Superior Performance of OGM in Variant Detection for Constitutional Genetic Diseases
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, hosted today the first of four days of 2022 Symposium, the Company’s premiere event showcasing OGM research applications across key clinical areas of constitutional genetic disease, hematologic... Read More
January 10, 2022
Bionano Genomics Hosts Day 1 of 2022 Symposium with Six Presentations Highlighting the Superior Performance of OGM in Variant Detection for Constitutional Genetic Diseases
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, hosted today the first of four days of 2022 Symposium, the Company’s premiere event showcasing OGM research applications across key clinical areas of constitutional genetic disease, hematologic... Read More
January 10, 2022
Bionano Genomics Announces Publication of Interim Readout from the Consortium Conducting a Postnatal Clinical Trial Intended to Support Establishing Optical Genome Mapping as Part of Standard of Care in Genetic Disease Diagnosis
IRB-approved, multi-site, ongoing study evaluated 331 individual sample runs from 202 unique samples across 5 sites for interim measures of key endpoints: Concordance with standard of care (SOC) – 97.7% [214 out of 219 samples] Partially concordant with SOC – 2.3% [5 out of 219 samples] Concordance with SOC for pathogenic variant calls – 100% [219 out of 219 samples] Concordance with chromosomal microarray (CMA) – 100% [103... Read More
January 7, 2022
Bionano Genomics Announces the Final Speaker Lineup for 2022 Symposium
27 different customers representing North America and Europe 31 oral presentations across four consecutive days Topics span the application of OGM in genetic disease and cancer research 45% of presentations are from North America and 55% are from Europe Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of the leading software solutions for visualization,... Read More
December 29, 2021
Bionano Announces Prototype for its Next Single Molecule Imaging System for OGM
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of the leading software solutions for visualization, interpretation and reporting of genomic data, today announced that it has completed the first prototype for its next single molecule imaging system for OGM. The prototype is being used to integrate and test the key engineering designs of a new instrument and... Read More
December 23, 2021
University Hospitals Leuven in Belgium Outlines their Menu Expansion Plans for Optical Genome Mapping as One of their Primary Analyses in Leukemias & Lymphomas and Genetic Disease
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of the leading software solutions for visualization, interpretation and reporting of genomic data, today announced that University Hospitals Leuven in Belgium, after previously receiving its accreditation from the Belgian Accreditation Body (BELAC) for using OGM in analysis of acute lymphoblastic leukemia... Read More
December 22, 2021
Bionano Genomics Appoints Vince Wong to its Board of Directors
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of the leading software solutions for visualization, interpretation and reporting of genomic data, today announced the appointment of Vincent Wong, JD, MBA, to its board of directors. Mr. Wong is currently the chief commercial officer at Geneoscopy, Inc., a life sciences company focused on the development of... Read More
December 16, 2021
Bionano Genomics Announces the Launch of Version 6.1 of BioDiscovery’s NxClinical Software for Genome Analysis with Expanded Capabilities for Visualization, Interpretation and Reporting of Next-Generation Sequencing Data in Genetic Diseases and...
Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr ® system and the leading software for genomic data visualization, interpretation and reporting, today announced the launch of version 6.1 of BioDiscovery’s N x Clinical software with expanded capabilities for next-generation sequencing (NGS) data in genetic diseases and cancer. N x Clinical is an industry-leading,... Read More
December 9, 2021
Bionano Genomics Announces 2022 Symposium Featuring Four Consecutive Days of OGM Presentations and Live Panel Discussions Delivered by 25 Different Customers Across a Wide Range of Genetic Disease and Cancer Applications
Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr ® system and the leading software for genomic data visualization, interpretation and reporting, today announced its 2022 Symposium featuring four consecutive days of OGM presentations delivered by 25 different customers worldwide across a wide range of genetic diseases and cancer applications. The Symposium will take place... Read More
December 8, 2021
Bionano Genomics Announces Publication of Study Evaluating Optical Genome Mapping for High Throughput Characterization of Cytogenomic Heterogeneity in MDS
Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr ® system and the leading software for genomic data visualization, interpretation and reporting, today announced the publication of a study of 76 subjects by authors at The University of Texas MD Anderson Cancer Center (MD Anderson), including Dr. Guillermo Garcia-Manero, Dr. Rashmi Kanagal-Shamanna and others. The study was... Read More
November 29, 2021
Bionano Genomics Appoints Dr. Keith Gligorich, Seasoned Leader in CLIA-Certified CAP-Accredited Lab Operations, as VP Operations for Bionano Laboratories
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of the leading software for genomic data visualization, interpretation and reporting, today announced that it has appointed Keith Gligorich, PhD, MB(ASCP) cm to the role of VP Operations for Bionano Laboratories. Keith was most recently with Guarant Health where he led the build-out of Guardant’s... Read More
November 22, 2021
Bionano Genomics Announces Peer-Reviewed Publication from Johns Hopkins University Outlining a Stepwise Approach to the Adoption of Optical Genome Mapping for Cancer Analysis
Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr ® system and the leading software for genomic data visualization, interpretation and reporting, today announced the publication of a study by Johns Hopkins University in the Journal of Clinical & Anatomic Pathology outlining a stepwise approach to adoption of OGM for cancer analysis in the cytogenetics lab. “This publication is by... Read More
November 15, 2021
Bionano Genomics Announces Extensive Lineup of Content to be Presented at the Annual Meeting of the Association for Molecular Pathology Featuring Optical Genome Mapping Across a Broad Range of Clinical Research Applications
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) and provider of industry-leading data interpretation solutions for next-generation sequencing (NGS) and microarrays, today announced the lineup of content scheduled to be presented at the annual meeting of the Association for Molecular Pathology (AMP). The content is expected to include an oral platform presentation by Dr. Ravi Kolhe at Augusta Universty,... Read More
November 4, 2021
Bionano Genomics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Progress
Acquisition of BioDiscove ry transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics Total revenue of $4.7 million , a 112% year-over-year total revenue increase, driven by growth in the Saphyr® installed base Record number of Saphyr shipments and installations for any quarter to date Launched protocols... Read More

COPYRIGHT ©2023 HEALTH STOCKS HUB